Martínez-López, Joaquín http://orcid.org/0000-0001-7908-0063
Mateos, María-Victoria http://orcid.org/0000-0003-2390-1218
Encinas, Cristina
Sureda, Anna
Hernández-Rivas, José Ángel
Lopez de la Guía, Ana
Conde, Diego
Krsnik, Isabel
Prieto, Elena
Riaza Grau, Rosalía
Gironella, Mercedes http://orcid.org/0000-0002-8106-8909
Blanchard, María Jesús
Caminos, Nerea
Fernández de Larrea, Carlos
Senin, María Alicia
Escalante, Fernando
de la Puerta, José Enrique http://orcid.org/0000-0003-2563-7510
Giménez, Eugenio
Martínez-Barranco, Pilar
Mateos, Juan José
Casado, Luis Felipe
Bladé, Joan
Lahuerta, Juan José http://orcid.org/0000-0002-3393-9570
de la Cruz, Javier
San-Miguel, Jesús http://orcid.org/0000-0002-9183-4857
Article History
Received: 31 July 2020
Revised: 6 August 2020
Accepted: 6 August 2020
First Online: 19 October 2020
Conflict of interest
: M.-V.M. has received honoraria for lectures and participation in advisory boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seatle Genetics, Pfizer, and Regeneron. J.M.-L. has received honoraria for participation in advisory boards from Novartis, Roche, BMS, Adaptive, Incyte, Amgen, and Janssen-Cilag. J.S.-M. has received honoraria for lectures and advisory boards from Amgen, Bristol–Myers Squibb, Celgene, Janssen, Merck, Novartis, Takeda, Sanofi, and Roche. J.B. has received honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. J.J.L. has received honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, and Takeda. A.L. has received honoraria for advisory boards from Celgene, Amgen, and Janssen. P.M.-B. has received honoraria for advisory boards from Amgen. A.S. has received honoraria for advisory boards from Takeda, BMS, MSD, Sanofi, Roche, Novartis, Janssen, and Sandoz, and for a consultancy from Takeda, BMS, Novartis, Celgene, Janssen, Gilead, and Sanofi, and has received honoraria as a member of a Speakers Bureau for Takeda. F.E. has received honoraria for advisory boards from Celgene and Amgen. E.P.P. has received honoraria for advisory boards from Amgen and for lectures from BMS/Celgene and Janssen. C.F.d.L. has received honoraria for advisory boards from BMS/Celgene, Amgen, Takeda, and Janssen. L.F.C. reports honoraria for lectures from and membership on advisory boards with Celgene, Janssen, Roche, Novartis, Bristol–Myers Squibb, Amgen, Takeda, Pfizer, Incyte, and AbbVie. The remaining authors declare that they have no conflict of interest.